Akebia Therapeutics, Inc.

Equities

AKBA

US00972D1054

Biotechnology & Medical Research

Delayed Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.83 USD -18.30% Intraday chart for Akebia Therapeutics, Inc. -10.29% +47.58%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Advance Premarket Thursday MT
Sector Update: Health Care MT
Transcript : Akebia Therapeutics, Inc. - Special Call
Akebia Therapeutics Shares Jump Pre-Bell on FDA Approval of Anemia Treatment for Chronic Kidney Disease Dialysis Patients MT
Akebia Shares Rally Premarket After FDA Approves Vafseo DJ
U.S. FDA approves Akebia's anemia drug RE
U.S. FDA approves Akebia's anemia drug RE
Akebia Therapeutics, Inc. Receives FDA Approval of Vafseo Tablets for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis CI
Akebia Therapeutics, Inc. Announces Management Changes, Effective March 22, 2024 CI
Akebia Therapeutics, Inc. Announces Executive Changes, Effective March 22, 2024 CI
Akebia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (AKBA) AKEBIA THERAPEUTICS Posts Q4 Revenue $56.2M, vs. Street Est of $55.4M MT
Akebia Therapeutics, Inc. Provides Revenue Guidance for the Year 2024 CI
Akebia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Akebia Therapeutics, Inc. Secures $55 Million Term Loan Financing CI
Transcript : Akebia Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 11:15 AM
Akebia Therapeutics Names Nicholas Grund as Chief Commercial Officer MT
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer CI
Akebia Therapeutics, Inc. Announces the Appointment of Richard C. Malabre as Chief Accounting Officer and Principal Accounting Officer CI
HC Wainwright Adjusts Price Target on Akebia Therapeutics to $5 From $3.75, Maintains Buy Rating MT
Transcript : Akebia Therapeutics, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Earnings Flash (AKBA) AKEBIA THERAPEUTICS Posts Q3 Revenue $42M MT
Akebia Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
Akebia Therapeutics, Inc. Enters into the Fourth Amendment to Loan Agreement CI
Chart Akebia Therapeutics, Inc.
More charts
Akebia Therapeutics, Inc. is an integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics that serve as a foundation for future growth. The Company's portfolio includes Auryxia (ferric citrate), Vafseo (vadadustat), and HIF-PH inhibitors. Auryxia is a non-calcium, non-chewable, orally administered tablet, which controls the serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease, (DD-CKD), or the hyperphosphatemia Indication, and the treatment of iron deficiency anemia. Vafseo (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, that is approved in Japan for the treatment of anemia due to chronic kidney disease (CKD), in adult patients. The Company utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.83 USD
Average target price
5 USD
Spread / Average Target
+173.22%
Consensus
  1. Stock
  2. Equities
  3. Stock Akebia Therapeutics, Inc. - Nasdaq
  4. News Akebia Therapeutics, Inc.
  5. Akebia Therapeutics Anemia Drug Application Fails to Secure FDA Approval -- Shares Plunge